NBIX - Neurocrine Biosciences Inc - SEC Form 4 Insider Trading Screener

Manufactured Goods - Chemicals - Biological Products, (No Diagnostic Substances) - NBIX (914475)
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
Real-time CSV, Options, Alerts
86 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
S68+2-1-3+9

X

Filing Date

Trade Date

Ticker

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

D
2017-11-15
NBIXLippoldt DarinGCS - Sale+OE$73.05-9,90013,157-43%-$723,191
2017-11-08
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$74.58-30,00077,691-28%-$2,237,343
D
2017-11-02
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$69.71-52,81748,973-52%-$3,681,641
D
2017-11-02
NBIXGano KyleChief Business Development OffS - Sale+OE$71.05-24,81873,246-25%-$1,763,319
D
2017-10-02
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$61.04-6,92548,973-12%-$422,702
D
2017-09-06
NBIXGano KyleChief Business Development OffS - Sale+OE$60.00-20,39373,246-22%-$1,223,580
D
2017-09-06
NBIXLippoldt DarinGCS - Sale+OE$60.00-10013,157-1%-$6,000
D
2017-09-06
NBIXGano KyleChief Business Development OffS - Sale+OE$60.00-4,60773,246-6%-$276,420
D
2017-09-06
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale+OE$60.00-26,250129,601-17%-$1,575,000
D
2017-09-05
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$57.50-52,81748,973-52%-$3,036,978
D
2017-08-09
NBIXLippoldt DarinGCS - Sale+OE$55.00-5,00013,157-28%-$275,000
D
2017-08-09
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale+OE$55.00-15,354107,691-12%-$844,470
D
2017-08-04
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale+OE$50.00-22,500129,601-15%-$1,125,000
D
2017-07-27
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$50.00-8,73448,973-15%-$436,700
2017-05-23
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$53.39-10,000107,691-8%-$533,900
D
2017-05-18
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$53.32-105,63448,973-68%-$5,632,405
DM
2017-05-18
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale+OE$53.63-9,96013,017-43%-$534,155
D
2017-05-18
NBIXLippoldt DarinGCS - Sale+OE$53.27-10,00013,157-43%-$532,700
2017-05-05
NBIXNevinny Corinne HDirS - Sale$53.98-5,00034,603-13%-$269,900+2+4
2017-05-02
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$55.00-10,000117,691-8%-$550,0000-2
D
2017-05-02
NBIXGorman Kevin CharlesCEOS - Sale+OE$53.23-21,739332,607-6%-$1,157,1670-2
D
2017-05-01
NBIXGano KyleChief Business Development OffS - Sale+OE$54.00-15,00073,246-17%-$810,0000-2
2017-04-12
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$50.42-13,06548,973-21%-$658,774+2-40
2017-04-12
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale$50.42-13,06513,017-50%-$658,774+2-40
2017-04-12
NBIXLippoldt DarinGCS - Sale$50.42-13,06513,157-50%-$658,774+2-40
2017-04-12
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$50.42-13,065127,691-9%-$658,774+2-40
2017-04-12
NBIXGorman Kevin CharlesCEOS - Sale$50.42-19,596332,607-6%-$988,085+2-40
2017-04-12
NBIXGano KyleChief Business Development OffS - Sale$50.42-13,06573,246-15%-$658,774+2-40
2017-04-12
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$50.42-13,065129,601-9%-$658,774+2-40
D
2017-02-06
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale+OE$43.13-727115,756-1%-$31,356+3-5+2
D
2017-02-06
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale+OE$43.14-963117,666-1%-$41,544+3-5+2
D
2017-02-06
NBIXGano KyleChief Business Development OffS - Sale+OE$43.15-72761,311-1%-$31,370+3-5+2
DM
2017-02-06
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale+OE$43.35-8431,082-44%-$36,545+3-5+2
D
2017-02-06
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$43.17-1,20637,038-3%-$52,063+3-5+2
DM
2017-02-06
NBIXBenevich EricChief Commercial OfficerS - Sale+OE$43.32-9531,222-44%-$41,287+3-5+2
DM
2017-02-06
NBIXLippoldt DarinGCS - Sale+OE$43.34-9531,222-44%-$41,300+3-5+2
2017-02-06
NBIXCoughlin Timothy PCFOS - Sale$43.14-963137,961-1%-$41,544+3-5+2
D
2017-02-06
NBIXGorman Kevin CharlesCEOS - Sale+OE$43.18-3,010314,703-1%-$129,972+3-5+2
2017-02-03
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$42.57-1,375116,079-1%-$58,534+1+3+1
2017-02-03
NBIXCoughlin Timothy PCFOS - Sale$42.55-1,500136,324-1%-$63,825+1+3+1
2017-02-03
NBIXGano KyleChief Business Development OffS - Sale$42.57-1,37560,113-2%-$58,534+1+3+1
2017-02-03
NBIXGorman Kevin CharlesCEOS - Sale$42.55-3,125247,802-1%-$132,969+1+3+1
2017-02-03
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$42.56-1,375114,558-1%-$58,520+1+3+1
2017-02-03
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$42.50-1,50035,044-4%-$63,750+1+3+1
D
2017-02-01
NBIXRastetter William HDirS - Sale+OE$42.28-10,75014,250-43%-$454,510+3+4+4
2017-01-17
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$40.63-1,625114,704-1%-$66,024-1-5+1
2017-01-17
NBIXCoughlin Timothy PCFOS - Sale$40.65-1,750134,824-1%-$71,138-1-5+1
2017-01-17
NBIXGano KyleChief Business Development OffS - Sale$40.65-1,62558,738-3%-$66,056-1-5+1
2017-01-17
NBIXGorman Kevin CharlesCEOS - Sale$40.65-3,750244,677-2%-$152,438-1-5+1
2017-01-17
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$40.63-1,625113,183-1%-$66,024-1-5+1
2017-01-17
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$40.66-1,75033,544-5%-$71,155-1-5+1
2017-01-10
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$43.35-1,75031,794-5%-$75,863+3+1+8
2017-01-10
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$43.39-1,625111,558-1%-$70,509+3+1+8
2017-01-10
NBIXGorman Kevin CharlesCEOS - Sale$43.28-3,750240,927-2%-$162,300+3+1+8
2017-01-10
NBIXGano KyleChief Business Development OffS - Sale$43.37-1,25057,113-2%-$54,213+3+1+8
2017-01-10
NBIXCoughlin Timothy PCFOS - Sale$43.37-1,750133,124-1%-$75,898+3+1+8
2017-01-10
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$43.37-1,625113,079-1%-$70,476+3+1+8
2016-11-15
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$52.84-25,00030,044-45%-$1,321,000-3-7-17
D
2016-09-01
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale+OE$50.00-9,0000-100%-$450,000-1-20-13
2016-08-15
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$48.73-12,50055,044-19%-$609,125-1+7+7-14
2016-08-08
NBIXNevinny Corinne HDirS - Sale$48.54-5,00025,555-16%-$242,700-30+4-11
D
2016-05-31
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale+OE$50.00-9,0000-100%-$450,000-2+2-11-5
2016-05-31
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$50.00-12,50067,544-16%-$625,000-2+2-11-5
2016-05-25
NBIXPops Richard FDirS - Sale$46.72-15,00015,464-49%-$700,800+1+11-5+7
2016-05-16
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$45.00-25,00080,044-24%-$1,125,000+3+7+1+21
D
2016-04-11
NBIXGano KyleChief Business Development OffS - Sale+OE$44.02-41,77055,863-43%-$1,838,511+20-8+1
2016-04-06
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$45.00-25,000105,044-19%-$1,125,000-4+3-6+13
2016-02-03
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$38.01-1,500130,044-1%-$57,015-3-8-4+34
2016-02-03
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$37.98-1,375109,933-1%-$52,223-3-8-4+34
2016-02-03
NBIXGorman Kevin CharlesPres, CEOS - Sale$38.04-3,125228,077-1%-$118,875-3-8-4+34
2016-02-03
NBIXGano KyleChief Business Development OffS - Sale$37.98-1,37555,863-2%-$52,223-3-8-4+34
2016-02-03
NBIXCoughlin Timothy PCFOS - Sale$38.06-1,500131,374-1%-$57,090-3-8-4+34
2016-02-03
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$38.13-1,375111,454-1%-$52,429-3-8-4+34
2016-01-19
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$46.77-1,750128,544-1%-$81,848+2-10-24-1
2016-01-19
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$46.76-1,625108,558-1%-$75,985+2-10-24-1
2016-01-19
NBIXGorman Kevin CharlesPres, CEOS - Sale$46.70-3,750224,952-2%-$175,125+2-10-24-1
2016-01-19
NBIXGano KyleChief Business Development OffS - Sale$46.84-1,62554,488-3%-$76,115+2-10-24-1
2016-01-19
NBIXCoughlin Timothy PCFOS - Sale$46.69-1,750129,874-1%-$81,708+2-10-24-1
2016-01-19
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$46.77-1,625110,079-1%-$76,001+2-10-24-1
2016-01-11
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$44.25-1,750126,794-1%-$77,438+14+17-14+10
2016-01-11
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$44.21-1,625106,933-1%-$71,841+14+17-14+10
2016-01-11
NBIXGorman Kevin CharlesPres, CEOS - Sale$44.17-3,750221,202-2%-$165,638+14+17-14+10
2016-01-11
NBIXGano KyleChief Business Development OffS - Sale$44.23-1,25052,863-2%-$55,288+14+17-14+10
2016-01-11
NBIXCoughlin Timothy PCFOS - Sale$44.25-1,750128,124-1%-$77,438+14+17-14+10
2016-01-11
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$44.25-1,625108,454-1%-$71,906+14+17-14+10
D
2015-11-27
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale+OE$57.50-10,000105,308-9%-$575,000-2-5+4-9

Real-time CSV? Options? Alerts? Contact us!
AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top